Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chinese herbal compound for treating pubertal polycystic ovary syndrome

A polycystic ovary syndrome technology, which is applied in the field of traditional Chinese medicine for the treatment of adolescent polycystic ovary syndrome, can solve the problems of repeated abnormal features, elevated leptin and high-sensitivity C-reactive protein, and is not suitable for the treatment of adolescent PCOS.

Active Publication Date: 2016-05-25
侯丽辉
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A study observed the effect of contraceptives on obese adolescent PCOS. After treatment, the serum total testosterone and free androgen index of patients decreased significantly, but the improvement of blood lipid was not good, and the total cholesterol and low-density lipoprotein increased significantly.
Another study found that Yasmin did not reduce total cholesterol, and leptin and high-sensitivity C-reactive protein increased significantly after treatment, which means that Yasmin increases the risk of heart disease
Metformin is an insulin sensitizer that is mainly used to treat diseases such as insulin resistance or metabolic syndrome. A survey study showed that the use of metformin is increasing year by year among adolescent girls, and PCOS is the main reason, but a study proposed that metformin It is not suitable for the treatment of adolescent PCOS. Once the drug is stopped, all abnormal features will recur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chinese herbal compound for treating pubertal polycystic ovary syndrome
  • Chinese herbal compound for treating pubertal polycystic ovary syndrome
  • Chinese herbal compound for treating pubertal polycystic ovary syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] A traditional Chinese medicine compound for treating adolescent polycystic ovary syndrome. The formula is proportioned by weight and contains 35 parts of astragalus, 25 parts of American ginseng, 20 parts of salvia miltiorrhiza, 20 parts of hawthorn, 20 parts of poria cocos, 25 parts of atractylodes macrocephala and 20 parts of tangerine peel.

[0013] The dosage form of this compound is granule and decoction;

[0014] Usage and Dosage: Granules, 1 dose of water, take it with water, once in the morning and evening, one month as a course of treatment; decoction, 1 dose of water decoction, once in the morning and evening, one month as a course of treatment;

[0015] Taking grams: 130g / day;

[0016] 45 cases of adolescent PCOS were treated with traditional Chinese medicine compound intervention: the serum LH, LH / FSH, T, AND levels of the patients were significantly lower than those before treatment, which was statistically significant (P<0.05); the serum TC and APOB levels...

Embodiment 2

[0018] A traditional Chinese medicine compound for treating polycystic ovary syndrome in adolescence. The formula is proportioned by weight, including 30 parts of astragalus, 20 parts of American ginseng, 15 parts of salvia miltiorrhiza, 15 parts of hawthorn, 15 parts of poria cocos, 20 parts of atractylodes macrocephala and 15 parts of tangerine peel.

[0019] The dosage form of this compound is granule and decoction;

[0020] Usage and Dosage: Granules, 1 dose of water, take it with water, once in the morning and evening, one month as a course of treatment; decoction, 1 dose of water decoction, once in the morning and evening, one month as a course of treatment;

[0021] Taking grams: 130g / day;

[0022] 45 cases of adolescent PCOS were treated with traditional Chinese medicine compound intervention for three months: the levels of serum LH, LH / FSH, T, AND were significantly lower than those before treatment, which was statistically significant (P<0.05); after treatment, the l...

Embodiment 3

[0024] Acute toxicity test data

[0025] Test Unit: Heilongjiang University of Traditional Chinese Medicine

[0026] Test start and end date: 2015.11.~2015.12

[0027] Preservation location of original data: Experimental Center of Heilongjiang University of Traditional Chinese Medicine

[0028] Determination of the maximum dosage of compound preparation

[0029] OBJECTIVE: To observe the possible toxic reaction of the compound preparation by intragastric administration, and to provide a reference for clinical safe drug use. Content: The compound preparation was administered to mice with a maximum concentration of 1.86g / ml and a maximum volume of 0.4ml / 10g, and no LD was detected by intragastric administration for the second time 50 . Therefore, the maximum dosage was determined: with the maximum concentration of 1.86g / ml and the maximum volume of 0.4ml / 10g, the drug was given twice by intragastric administration.

[0030] Conclusion: The maximum dosage of oral administrat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Average ageaaaaaaaaaa
Login to View More

Abstract

The invention provides a Chinese herbal compound for treating the pubertal polycystic ovary syndrome. The Chinese herbal compound is prepared from, by weight, 30-35 parts of radix astragali, 20-25 parts of American ginseng, 15-20 parts of Radix Salviae Miltiorrhizae,, 15-20 parts of hawthorn, 15-20 parts of poria cocos, 20-25 parts of bighead atractylodes rhizome and 15-20 parts of tangerine peel. The pubertal polycystic ovary syndrome (PCOS) is treated through the method of tonifying qi and spleens, reducing phlegm, activating blood and regulating constitution; compared with other traditional Chinese medicine research, the Chinese herbal compound can reduce levels of luteinizing hormone (LH), luteinizing hormone / follicle-stimulating hormone (LH / FSH), testosterone (T) and androstenedione (AND) in serum of patients and also can reduce the levels of total cholesterol (TC) and apolipoprotein B (APOB) in blood fat, and therefore the aims of regulating the menstrual cycle, improving hyperandrogenism and correcting dyslipidemia are achieved.

Description

technical field [0001] The invention relates to a traditional Chinese medicine compound for treating adolescent polycystic ovary syndrome. Background technique [0002] Polycystic ovary syndrome is a common endocrine disease in women of childbearing age, with an incidence rate of 6%-15%, starting in adolescence. In recent years, the incidence of PCOS in adolescence has gradually increased, and it has been paid more and more attention by clinicians. Because the physiological characteristics of puberty overlap with the symptoms and signs of PCOS, PCOS-related consensus and guidelines recommend that the diagnostic criteria for PCOS in puberty must meet the three diagnostic criteria of Rotterdam and menstruation for more than 2 years: ① Oligomenorrhea after menarche, amenorrhea or primary amenorrhea2 More than one year; ②Clinical manifestations of hyperandrogenism and androgen excess; ③Abdominal ultrasound findings: Ovarian volume must be >10cm 3 , ≥12 follicles with a diam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/752A61P15/00A61P5/00
CPCA61K36/076A61K36/258A61K36/284A61K36/481A61K36/537A61K36/734A61K36/752A61K2300/00
Inventor 侯丽辉
Owner 侯丽辉
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com